局部晚期宫颈癌放疗同期洛铂化疗疗效分析
|
摘要
目的探析局部晚期宫颈癌患者采用放射治疗同期联合洛铂化疗的近期疗效及安全性。方法选取本院2013年1月—2015年12月接收的90例局部晚期宫颈癌患者,根据治疗方式的不同将其分为观察组与对照组,每组45例,观察组接受放疗同期联合洛铂化疗、对照组接受放疗同期联合顺铂化疗。对比近期疗效以及不良反应发生情况。结果观察组治疗近期总有效率与对照组比较差异无统计学意义(P>0.05)。观察组骨髓抑制发生率高于对照组且其胃肠道反应低于对照组(P <0.05);两组肝肾功能损伤和放射性直肠炎对比差异无统计学意义(P> 0.05)。结论局部晚期宫颈癌患者接受放疗的同时加以洛铂同期化疗临床疗效肯定,并能够降低患者的不良反应。
Objective To investigate the short-term efficacy and safety of concurrent radiotherapy combined with lobaplatin chemotherapy in patients with locally advanced cervical cancer. Methods 90 cases of patients with locally advanced cervical cancer received from January 2013 to December 2015 were divided into observation group and control group according to different treatment methods, 45 cases in each group. The observation group was received radiotherapy, in the same period, combined with lobaplatin chemotherapy, the control group was received radiotherapy combined with cisplatin chemotherapy. The short-term efficacy and the occurrence of adverse reactions and quality of life scores were compared. Results There was no significant difference in the short-term total effective rate between the observation group and the control group(P > 0.05). The incidence of bone marrow suppression in the observation group was higher than that in the control group, and the gastrointestinal reaction in the observation group was lower than that in the control group(P < 0.05). There was no significant difference in liver and kidney function damage and radiation proctitis between the two groups(P > 0.05). Conclusion Patients with locally advanced cervical cancer receive radiotherapy and have a positive clinical effect with concurrent platinum-platinum chemotherapy, and can reduce the adverse reactions of patients.
Objective To investigate the short-term efficacy and safety of concurrent radiotherapy combined with lobaplatin chemotherapy in patients with locally advanced cervical cancer. Methods 90 cases of patients with locally advanced cervical cancer received from January 2013 to December 2015 were divided into observation group and control group according to different treatment methods, 45 cases in each group. The observation group was received radiotherapy, in the same period, combined with lobaplatin chemotherapy, the control group was received radiotherapy combined with cisplatin chemotherapy. The short-term efficacy and the occurrence of adverse reactions and quality of life scores were compared. Results There was no significant difference in the short-term total effective rate between the observation group and the control group(P > 0.05). The incidence of bone marrow suppression in the observation group was higher than that in the control group, and the gastrointestinal reaction in the observation group was lower than that in the control group(P < 0.05). There was no significant difference in liver and kidney function damage and radiation proctitis between the two groups(P > 0.05). Conclusion Patients with locally advanced cervical cancer receive radiotherapy and have a positive clinical effect with concurrent platinum-platinum chemotherapy, and can reduce the adverse reactions of patients.
引文
[1]崔杰.不同化疗方案同期联合放疗治疗中晚期宫颈癌的疗效分析[J].中国老年保健医学,2016,14(5):49-51.
[2]李凤虎,杨飞月,常建英,等.宫颈癌紫杉醇联合洛铂或顺铂新辅助序贯洛铂或顺铂同步化放疗多中心随机临床研究[J].中华肿瘤防治杂志,2016,23(16):1090-1094.
[3]冯奉仪.实体瘤新的疗效评价标准(解读1.1版RECIST标准)[A].中国癌症基金会,中国抗癌协会肿瘤临床化疗专业委员会,中华医学会肿瘤学分会,全国肿瘤防治研究办公室,中国医学科学院肿瘤医院.第三届中国肿瘤内科大会教育集暨论文集[C].中国癌症基金会,中国抗癌协会肿瘤临床化疗专业委员会,中华医学会肿瘤学分会,全国肿瘤防治研究办公室,中国医学科学院肿瘤医院:中国抗癌协会,2009:3.
[4]廖思辉,王芳芳,陈运强,等.奈达铂、顺铂联合同期放疗治疗局部中晚期宫颈癌的疗效及急性毒副反应比较[J].广西医学,2017,39(9):1328-1331.
[5]高艳丽.宫颈癌患者调强放疗(IMRT)联合顺铂治疗的临床疗效及不良反应[J].当代医学,2016,22(35):64-65.
[6]叶玲.中晚期宫颈癌调强放疗联合同步化疗与常规放疗联合同步化疗临床疗效及不良反应对比观察[J].临床和实验医学杂志,2016,15(1):51-54.
[7]柯丽娟,孙阳,刘佳华,等.术前应用洛铂联合紫杉醇新辅助化疗方案对局部宫颈癌晚期患者的疗效及预后研究[J].肿瘤药学,2016,6(6):442-445,450.
[8]李霞,孔为民,陈娇,等.两种同步化疗方案联合放疗对中晚期宫颈癌疗效及不良反应比较[J].癌症进展,2016,14(12):1264-1267.
[9]张印星,潘春燕,陈小刚.紫杉醇联合洛铂新辅助化疗治疗局部晚期宫颈癌的疗效及其对患者血清Dc R3及Survivin的影响[J].海南医学,2016,27(18):2948-2951.
[10]刘静,余梦虹,张丛敏,等.吉西他滨联合洛铂介入栓塞对局部晚期宫颈癌患者疗效及免疫-炎症因子水平的影响[J].广西医学,2017,39(3):326-330.
[11]刘瑛,张余琴,杨振华,等.同步推量调强放疗联合化疗治疗局部中晚期宫颈癌的疗效和安全性[J].肿瘤,2017,37(9):974-980.
[12]陈丽.多西紫杉醇与紫杉醇联合顺铂放化疗治疗宫颈癌的疗效对比[J].中国继续医学教育,2018,10(25):131-132.
[13]李慧卿.不同化疗方案同期联合放疗治疗中晚期宫颈癌的临床效果分析[J].中国卫生标准管理,2017,8(16):90-92.
[2]李凤虎,杨飞月,常建英,等.宫颈癌紫杉醇联合洛铂或顺铂新辅助序贯洛铂或顺铂同步化放疗多中心随机临床研究[J].中华肿瘤防治杂志,2016,23(16):1090-1094.
[3]冯奉仪.实体瘤新的疗效评价标准(解读1.1版RECIST标准)[A].中国癌症基金会,中国抗癌协会肿瘤临床化疗专业委员会,中华医学会肿瘤学分会,全国肿瘤防治研究办公室,中国医学科学院肿瘤医院.第三届中国肿瘤内科大会教育集暨论文集[C].中国癌症基金会,中国抗癌协会肿瘤临床化疗专业委员会,中华医学会肿瘤学分会,全国肿瘤防治研究办公室,中国医学科学院肿瘤医院:中国抗癌协会,2009:3.
[4]廖思辉,王芳芳,陈运强,等.奈达铂、顺铂联合同期放疗治疗局部中晚期宫颈癌的疗效及急性毒副反应比较[J].广西医学,2017,39(9):1328-1331.
[5]高艳丽.宫颈癌患者调强放疗(IMRT)联合顺铂治疗的临床疗效及不良反应[J].当代医学,2016,22(35):64-65.
[6]叶玲.中晚期宫颈癌调强放疗联合同步化疗与常规放疗联合同步化疗临床疗效及不良反应对比观察[J].临床和实验医学杂志,2016,15(1):51-54.
[7]柯丽娟,孙阳,刘佳华,等.术前应用洛铂联合紫杉醇新辅助化疗方案对局部宫颈癌晚期患者的疗效及预后研究[J].肿瘤药学,2016,6(6):442-445,450.
[8]李霞,孔为民,陈娇,等.两种同步化疗方案联合放疗对中晚期宫颈癌疗效及不良反应比较[J].癌症进展,2016,14(12):1264-1267.
[9]张印星,潘春燕,陈小刚.紫杉醇联合洛铂新辅助化疗治疗局部晚期宫颈癌的疗效及其对患者血清Dc R3及Survivin的影响[J].海南医学,2016,27(18):2948-2951.
[10]刘静,余梦虹,张丛敏,等.吉西他滨联合洛铂介入栓塞对局部晚期宫颈癌患者疗效及免疫-炎症因子水平的影响[J].广西医学,2017,39(3):326-330.
[11]刘瑛,张余琴,杨振华,等.同步推量调强放疗联合化疗治疗局部中晚期宫颈癌的疗效和安全性[J].肿瘤,2017,37(9):974-980.
[12]陈丽.多西紫杉醇与紫杉醇联合顺铂放化疗治疗宫颈癌的疗效对比[J].中国继续医学教育,2018,10(25):131-132.
[13]李慧卿.不同化疗方案同期联合放疗治疗中晚期宫颈癌的临床效果分析[J].中国卫生标准管理,2017,8(16):90-92.